Even with the best management, best results and best benefits no one wants it. Seems that everyone that is against this solution and believes that we need to carry on with IV morphine for the next 50 years . This is much bigger that any stock price. This is about providing an industry breakthrough by offering safer, more effective and easier care to millions of people. No ones seems to care. Perhaps most that is against this company, stocks or solution will experience the agony of mistreated IV morphine or maybe see your loved one in misery or die. When that happens don't come crying, no one will be listening, enjoy your IV and obviously you've messed it up for the rest of us.
Who knows how far the market will crash due to one idiot.
Most Bios are 20% up from their year levels before starting the run up. ACRX was 20% down and it did not even obtain an opportunity or chance. The company valuation and where the stock price should be are so far removed, ACRX submitted EU application and obtain a $5 mil milestone payment and this was completely ignored.
Yellen make such an irresponsible comment as to say valuations in the Bio sector appear substantially stretched when valuations are not comparable, Smaller Bios such as ACRX is 20% down for the year before the announcement. How can you have such an idiot in such a power position. ACRX is now 40% in oversold.
Go back to the KERX message board, remember what happened there. Read the Roth Capital paper from yesterday and try to apply some intelligence in your posts.
In a research report released yesterday, Roth Capital analyst Ed Arce reiterated a Buy rating on AcelRx Pharmaceuticals Inc. (ACRX) with a price target of $22.00, following yesterday’s news that ACRX’s EU marketing partner, Grunenthal, submitted a Marketing Authorization Application to the European Medicines Authority for ZALVISO for the management of moderate to severe acute pain in adult patients in a medically supervised environment.
Arce wrote, “Grunenthal filed Zalviso with the EMA, triggering a $5M milestone to AcelRx. We expect a mid-2015 approval and peak EU sales of $260M, with royalties to AcelRx of $40M. With Zalviso’s likely US approval this month and the initiation of a pivotal P3 trial of ARX-04 this year, we believe AcelRx continues to execute well, creating further shareholder value. We would be buyers ahead of the PDUFA”. The analyst added, “With multiple near-term catalysts, including the expected US commercial launch of Zalviso in 1Q15, we view ACRX shares as a strong, long-term growth holding within the sector. We recommend establishing or adding positions in ACRX shares ahead of the PDUFA date”.
Looking back 12 months and you can see that the PPS has not changed much - in addition now we have MAA EU filing plus $5 payment, the new pricing data has affected the market cap and we are a couple of days away from approval. We have significant space for upward movement since I don't believe that any of this has been baked into the current level as yet.
Funny that he always discloses his position afterwards as previous he had "sold" and then mysteriously when the stock goes up he has kept some. Its fine it he wants to play the game but no need for talking to himself via other ID's. Makes him look even more stupid.
Why do you keep talking to yourself? - your IDs were busted months ago - it is getting old, even you has to get tired of this, not healthy